Skip to main content
. 2020 Sep 3;6(1):48–56. doi: 10.1136/svn-2020-000422

Table 4.

Univariate and multivariate associations (according to three models*) of each log-biomarker with risk of all-cause death

Biomarker† Unadjusted Model 1 Model 2 Model 3 P value
HR (95% CI) P value HR (95% CI) HR (95% CI) HR (95% CI)
Inflammatory markers
 IL-6 1.34 (1.24 to 1.45) <0.001 1.33 (1.24 to 1.45) 1.33 (1.23 to 1.44) 1.31 (1.20 to 1.42) <0.001
 CRP 1.09 (0.98 to 1.22) 0.12 1.11 (0.99 to 1.25) 1.11 (0.99 to 1.24) 1.12 (0.99 to 1.25) 0.07
 NGAL 1.15 (1.03 to 1.29) 0.01 1.11 (0.99 to 1.24) 1.14 (1.02 to 1.28) 1.10 (0.98 to 1.24) 0.09
 sTNF-R1 1.43 (1.29 to 1.57) <0.001 1.34 (1.21 to 1.48) 1.42 (1.27 to 1.58) 1.38 (1.24 to 1.54) <0.001
Thrombotic or antiatherogenic markers
 TM 1.07 (0.97 to 1.18) 0.20 1.01 (0.91 to 1.12) 1.03 (0.93 to 1.15) 1.04 (0.93 to 1.16) 0.50
 Fibrinogen 1.26 (1.13 to 1.41) <0.001 1.24 (1.11 to 1.39) 1.24 (1.11 to 1.39) 1.23 (1.10 to 1.37) <0.001
 vWF 1.43 (1.28 to 1.60) <0.001 1.38 (1.24 to 1.55) 1.40 (1.25 to 1.57) 1.40 (1.25 to 1.57) <0.001
 P-selectin 1.17 (1.06 to 1.28) 0.001 1.18 (1.07 to 1.30) 1.18 (1.07 to 1.30) 1.17 (1.07 to 1.29) 0.001
 PZ 0.96 (0.88 to 1.05) 0.34 0.98 (0.89 to 1.07) 0.98 (0.90 to 1.07) 0.98 (0.89 to 1.07) 0.59
 D-dimer 1.41 (1.27 to 1.56) <0.001 1.30 (1.17 to 1.45) 1.31 (1.18 to 1.47) 1.34 (1.20 to 1.50) <0.001
 Anti-PC 0.96 (0.87 to 1.05) 0.35 0.99 (0.90 to 1.09) 1.00 (0.91 to 1.10) 0.98 (0.89 to 1.08) 0.72
 ADAMTS-13 0.88 (0.80 to 0.98) 0.02 0.93 (0.84 to 1.03) 0.93 (0.84 to 1.03) 0.93 (0.83 to 1.03) 0.17
Markers of cardiac or neuronal function/injury
 NT-proBNP 1.45 (1.29 to 1.62) <0.001 1.34 (1.20 to 1.50) 1.37 (1.22 to 1.54) 1.34 (1.18 to 1.52) <0.001
 hFABP 1.49 (1.36 to 1.64) <0.001 1.40 (1.27 to 1.55) 1.59 (1.42 to 1.79) 1.59 (1.42 to 1.79) <0.001
 NSE 1.17 (1.08 to 1.27) <0.001 1.19 (1.09 to 1.29) 1.19 (1.10 to 1.30) 1.19 (1.10 to 1.30) <0.001
 BDNF 1.09 (1.01 to 1.17) 0.04 1.12 (1.04 to 1.21) 1.12 (1.03 to 1.21) 1.10 (1.02 to 1.19) 0.02

*Model 1: adjusted for age and sex; model 2 adjusted for variables in model 1 plus eGFR; model 3 adjusted for variables in model 2 plus hypertension, diabetes mellitus, previous myocardial infarction, previous peripheral vascular disease, previous ischaemic stroke, atrial fibrillation, current smoker, hyperlipidaemia, previous therapy with antiplatelet agents, statins or antihypertensive agents.

†Given per SD(Ln).

Anti-PC, antiphosphorylcholin; BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; hFABP, heart-type fatty-acid-binding protein; IL-6, interleukin-6; NGAL, neutrophil-gelatinase-associated lipocalin; NSE, neuron-specific enolase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PZ, Protein Z; sTNF-R1, soluble tumour necrosis factor receptor-1; TM, thrombomodulin; vWF, von Willebrand factor.